FDA Grants Rolling Review for CytoDyn’s Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140) Mar 04, 2019 6:00am EST
CytoDyn to Present New Data from Study of Investigational HIV Therapy Leronlimab (PRO 140), a Long-Acting, Single-Agent Maintenance Therapy at CROI 2019 Feb 27, 2019 6:00am EST
Leronlimab (PRO 140) reduces by more than 98% human breast cancer metastasis in mouse xenografts for over 6 weeks Feb 20, 2019 6:00am EST
CytoDyn to Initiate 8 Pre-Clinical Animal Studies with Leronlimab (PRO 140) for Melanoma, Pancreatic, Breast, Prostate, Colon, Lung, Liver, and Stomach Cancer at an Estimated Cost of $1.5 million, which Could Lead to 8 Phase 2 Clinical Studies Feb 19, 2019 6:00am EST
Uptick Newswire Hosts CytoDyn Inc. on Their Stock Day Podcast to Discuss Revenue Expectations for 2020 Feb 11, 2019 8:30am EST
CytoDyn Announces Productive Conference Call with FDA Regarding First BLA Submission for Leronlimab (PRO 140) Combination Therapy at 700 mg Dose Feb 01, 2019 6:00am EST
